Literatur
- 1
Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G.
Modulation of growth factor
binding properties of alpha-2-macroglobulin by enzyme therapy.
Cancer Chemother Pharmacol.
2001;
47
(Supplement)
S4-9
- 2
Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I.
Oral therapy with proteolytic
enzymes decreases excessive TGF-beta levels in human blood.
Cancer Chemother
Pharmacol.
2001;
47
(Supplement)
S10-15
- 3
Roberts A B, Sporn M B.
Physiological
actions and clinical applications of transforming growth factor-beta
(TGF-beta).
Growth Factors.
1993;
8
1
- 4
Kim S J, Angel P, Lafyatis R, Hattori K, Kim K Y, Sporn M B, Karin M, Roberts A B.
Autoinduction
of transforming growth factor beta 1 is mediated by the AP-1 complex.
Mol Cell Biol.
1990;
10
1492
- 5
Ruoslathi E, Yamaguchi Y, Hildebrand A, Border W A.
Extracellular
matrix/growth factor interactions.
Cold Spring
Harb Symp Quant Biol.
1992;
57
309
- 6
Taipale J, Sahrinen J, Hedman K, Keski O J.
Latent transforming
growth factor-beta 1 and ist binding protein are components of extracellular
matrix microfibrils.
J Histochem Cytochem.
1996;
44
875
- 7
Sakalova A, Bock P R, Dedik L, Hanisch J, Schiess W, Gazova S, Chabronova I, Holomanova D,
Mistrik M, Hrubisko M.
Retrolective cohort
study of an additive therapy with oral enzyme preparation in patients
with multiple myeloma.
Cancer Chemother Pharmacol.
2001;
47
(Supplement)
S38-44
- 8
Beuth J, Ost B, Pakdaman A, Rethfeldt E, Bock P R, Hanisch J, Schneider B.
Impact of complementary oral enzyme application on the postoperative
treatment results of breast cancer patients – results of
an epidemiological multicentre retrolective cohort study.
Cancer
Chemother Pharmacol.
2001;
47
(Supplement)
S45-54
- 9
Popiela T, Kulig J, Hanisch J, Bock P R.
Influence of
a complementary treatment with oral enzymes on patients with colorectal cancers –
an
epidemiological retrolective cohort study.
Cancer Chemother
Pharmacol.
2001;
47
(Suppl)
S55-63
- 10
Harthun N L, Weaver A M, Brinkerhoff L H, Deacon D H, Gonius S L, Slingluff C L.
Activated alpha(2)-macroglobulin reverses
the immunosuppressive activity in human breast cancer cell-conditioned
medium by selectively neutralizing transforming growth factor-beta
in the presence of interleukin-2.
J Immunother.
1998;
21
85
- 11
Kratsch J, Selisko T, Birkenmeier G.
Transformed alpha 2-macroglobulin as a low-affinitiy growth
hormone-binding protein.
Acta Paediatr Suppl.
1996;
417
108
- 12
Cardillo M R, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F.
Transforming
growth factor-beta expression in prostate neoplasia.
Anal
Quant Cytol Histol.
2000;
22
1
- 13
Gold L I.
The role for transforming growth factor-beta (TGF-beta) in human
cancer.
Crit Rev Oncog.
1999;
10
303
- 14
Liu P, Menon K, Alvarez E, Lu K, Teicher B A.
Transforming growth factor-beta and response to anticancer therapies
in human liver and gastric tumors in vitro and in vivo.
Int
J Oncol.
2000;
16
599
- 15
Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X F, Shimizu J, Fujiwara H,
Hamaoka T.
Transforming growth factor-beta-induced inhibition of T cell
function. Susceptibility difference in T cells of various phenotypes
and functions and its relevance to immunosuppression in the tumor-bearing
state.
J Immunol.
1991;
146
1077
- 16
Mumm J B, Oft M.
Cytokine-based transformation
of immune surveillance into tumor-promoting inflammation.
Oncogene.
2008;
27
(45)
5913-9
- 17
Ben-Baruch A.
Inflammation-associated immune suppression in cancer: the roles played
by cytokines, chemokines and additional mediators.
Semin
Cancer Biol.
2006;
16
(1)
38-52
, Epub 2005 Aug 31
- 18
Beuth J.
Integrative Onkologie: Therapie-optimierung durch komplementäre
Maßnahmen.
Integr Onkol.
2004;
1
6-11
Dr. Dr. med. Winfried Miller
Facharzt Allgemeinmedizin – Naturheilverfahren, Schwerpunktpraxis
für komplementäre Onkologie
Immenstädter
Str. 77a
87435 Kempten/Allgäu
Phone: 0831/59 48 66
Email: info@doktor-miller.de
